ConductScience.org, home

Paper32065631

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.

Cirrincione LR and 9 others. J Antimicrob Chemother, 2020. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. Papers, record 32065631. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32065631

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
2020
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
1.72
iCite
Revised in PubMed
2025-03-31
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cirrincione LRLauren R
2Podany ATAnthony T
3Havens JPJoshua P
4Bares SHSara H
5Dyavar SRShetty Ravi
6Gwon YYeongjin
7Johnson TMTanner M
8Amoura NJN Jean
9Fletcher CVCourtney V
10Scarsi KKKimberly K

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
HIV InfectionsMajor topic
Pharmaceutical PreparationsMajor topic
Pre-Exposure ProphylaxisMajor topic
Transgender PersonsMajor topic
Adult
Emtricitabine
Female
Hormones
Humans
Tenofovir
Male

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K23 AI134307NIAID NIH HHSUnited StatesK23AI134307PubMed and NIHNIH RePORTER
R01 AI124965NIAID NIH HHSUnited StatesR01AI124965PubMed and NIHNIH RePORTER
R01 HD085887NICHD NIH HHSUnited StatesR01HD085887PubMed and NIHNIH RePORTER
UM1 AI106701NIAID NIH HHSUnited StatesUM1AI106701PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03270969A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender WomenDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121091279Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.N Engl J Med2010https://conductscience.org/library/papers/21091279PubMed
227431475Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.J Int AIDS Soc2016https://conductscience.org/library/papers/27431475PubMed
331692269Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.J Int AIDS Soc2019https://conductscience.org/library/papers/31692269PubMed
425409469Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.Clin Infect Dis2015https://conductscience.org/library/papers/25409469PubMed
522972843Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Sci Transl Med2012https://conductscience.org/library/papers/22972843PubMed
617519400Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.J Clin Pharmacol2007https://conductscience.org/library/papers/17519400PubMed
731298497Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.J Int AIDS Soc2019https://conductscience.org/library/papers/31298497PubMed
823111578Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?J Acquir Immune Defic Syndr2013https://conductscience.org/library/papers/23111578PubMed
930963179Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.Clin Infect Dis2019https://conductscience.org/library/papers/30963179PubMed
1018025112Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18025112PubMed
1121118913Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.J Antimicrob Chemother2011https://conductscience.org/library/papers/21118913PubMed
1214643879Limitations of direct estradiol and testosterone immunoassay kits.Steroids2003https://conductscience.org/library/papers/14643879PubMed
1325065857Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.Lancet Infect Dis2014https://conductscience.org/library/papers/25065857PubMed
1427429187Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis.J Acquir Immune Defic Syndr2016https://conductscience.org/library/papers/27429187PubMed
1515290871P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.Pharm Res2004https://conductscience.org/library/papers/15290871PubMed
1616828350Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.J Chromatogr B Analyt Technol Biomed Life Sci2006https://conductscience.org/library/papers/16828350PubMed
1728075632Transgender Population Size in the United States: a Meta-Regression of Population-Based Probability Samples.Am J Public Health2017https://conductscience.org/library/papers/28075632PubMed
1824317955Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus.Ann Behav Med2014https://conductscience.org/library/papers/24317955PubMed
1923274933Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.J Acquir Immune Defic Syndr2013https://conductscience.org/library/papers/23274933PubMed
2028225438
Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis.
J Acquir Immune Defic Syndr2017https://conductscience.org/library/papers/28225438PubMed

See all 44 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42439052Special Issue: New Horizons in HIV and Reproductive Health Research: HIV Acquisition and Reproductive Health in Key Populations.Am J Reprod Immunol2026https://conductscience.org/library/papers/42439052PubMed
40390323No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study.J Int AIDS Soc2025https://conductscience.org/library/papers/40390323PubMed
40195242
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand.
J Int AIDS Soc2025https://conductscience.org/library/papers/40195242PubMed
38421210Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial.Clin Transl Sci2024https://conductscience.org/library/papers/38421210PubMed
38312459Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.Transgend Health2024https://conductscience.org/library/papers/38312459PubMed
37681452Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study.J Antimicrob Chemother2023https://conductscience.org/library/papers/37681452PubMed
37261664Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.Clin Pharmacokinet2023https://conductscience.org/library/papers/37261664PubMed
36416569Inclusion of Transgender and Gender Diverse People in Phase III Trials: Examples from HIV Pharmacologic Prevention Studies.Clin Pharmacol Ther2023https://conductscience.org/library/papers/36416569PubMed
35943868Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.AIDS Res Hum Retroviruses2022https://conductscience.org/library/papers/35943868PubMed
35815666
Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
J Antimicrob Chemother2022https://conductscience.org/library/papers/35815666PubMed
35815468Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.AIDS Res Hum Retroviruses2022https://conductscience.org/library/papers/35815468PubMed
35687813Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review.AIDS Patient Care STDS2022https://conductscience.org/library/papers/35687813PubMed
35285974Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.Br J Clin Pharmacol2022https://conductscience.org/library/papers/35285974PubMed
33404067Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus.Pharmacotherapy2021https://conductscience.org/library/papers/33404067PubMed
32724080Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics.Sci Rep2020https://conductscience.org/library/papers/32724080PubMed

Download CSV of cited by

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
TENOFOVIR DISOPROXIL FUMARATECHEMBL1486Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1486ChEMBL
EMTRICITABINE, (+/-)-CHEMBL161381Derived from the trial1https://conductscience.org/library/drugs/CHEMBL161381ChEMBL
EMTRICITABINECHEMBL885Derived from the trial1https://conductscience.org/library/drugs/CHEMBL885ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32065631

GET https://conductscience.org/api/papers/v1/32065631/references?page=2